Retatrutide
Phase 3aka LY3437943
Triple agonist (GLP-1, GIP, glucagon) in phase 3 for obesity. The one everyone's watching.
Mechanism
One molecule hitting three metabolic receptors at once: GLP-1, GIP, and glucagon. The glucagon arm is the interesting part, it bumps energy expenditure on top of the appetite suppression you already get from a GLP-1. On paper it should out-cut tirzepatide, and the phase 2 numbers backed that up.
Regulatory & Safety Status
Still investigational. Lilly's compound, no regulator has signed off, so everything you read is trial data. Anything sold to you right now is grey market.
Research
Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists
GLP-1, GIP, and Glucagon Receptor Agonism at the Obesity-Neurodegeneration Interface: A Narrative Review
Retatrutide treatment in streptozotocin-induced diabetic rats: renal inflammatory cytokines, HIF‑1α expression, and histopathological injury profile
Self-Reported Adverse Effects Among Social Media Users Taking Nonapproved Retatrutide
Retatrutide phase 2 obesity trial
Phase 2 RCT reporting dose-dependent weight reduction over 48 weeks.
Latest retatrutide research